Recombinant KRT17 antibody

Catalog No. ABIN7881374

The Rabbit Monoclonal anti-KRT17 antibody (Clone KRT17-8320R) (ABIN7881374) specifically detects KRT17 in IHC (p). The antibody is reactive with Human samples.

Quick Overview for Recombinant KRT17 antibody (ABIN7881374)

Target: KRT17 (Keratin 17 (KRT17))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This KRT17 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: KRT17-8320R

Product Details anti-KRT17 Antibody

Purpose: Recombinant Cytokeratin 17 Antibody / KRT17 (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: A recombinant fragment of the human protein was used as the immunogen for the recombinant Cytokeratin 17 antibody.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal dilution of the recombinant Cytokeratin 17 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the recombinant Cytokeratin 17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for KRT17

Target: KRT17 (Keratin 17 (KRT17))

Alternative Name: Cytokeratin 17

Background: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands, such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

UniProt: Q04695